Clinical Trial

Low-Dose Naltrexone For ME/CFS: Dose-Finding

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-12-09; most recent amendment 2026-05-11.
Trial Details
NCT Number NCT07285473
Lead Sponsor University of Alabama at Birmingham
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS)
Conditions Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Enrollment 75 participants
Start Date 2026-09-01
Primary Completion 2028-04-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-14